Browsing by Author "Oncel S."

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    Efficacy of nasal corticosteroids alone or combined with antihistamines or montelukast in treatment of allergic rhinitis
    (2008) Pinar E.; Eryigit O.; Oncel S.; Calli C.; Yilmaz O.; Yuksel H.
    Objective: Topical corticosteroids are recommended as initial therapy in allergic rhinitis (AR) patients. We investigated clinical efficacy of monotherapy with topical steroid and combined therapy in AR patients. Methods: Ninety-five AR patients sensitive to grass pollens according to skin prick test results were enrolled in this placebo-controlled and open study. Patients were divided to four groups. Group-1 received only intranasal mometasone furoate (MF) 200 μg (n = 25), group-2 received intranasal MF and oral desloratadine (DLR) 5 mg (n = 25), group-3 received intranasal MF and oral montelukast (MSK) 10 mg (n = 25), group-4 received only placebo (n = 20). Efficacy was assessed on the basis of total nasal symptom scores, rhinoconjunctivitis quality of life questionnaire scores and nasal inspiratory peak flow rates. Results: All groups that received treatment had better results when compared to the placebo group. Significant improvement in total nasal symptom scores was first evident at the end of the 2nd week in group-2. Group-3 had better results than those of the other groups at the end of the 1st month (p < 0.05). Quality of life scores were significantly better in group-2 and -3 when compared to those in group-1 (p < 0.05). Conclusion: Although corticosteroids are the mainstay of treatment in allergic rhinitis, montelukast may be considered as an additional agent especially in treatment of patients with impaired quality of life and it may be used to reduce nasal symptom scores. © 2007 Elsevier Ireland Ltd. All rights reserved.
  • No Thumbnail Available
    Item
    Translation and validation of the Turkish version of the Ankylosing Spondylitis Quality of Life (ASQOL) questionnaire
    (2013) Duruöz M.T.; Doward L.; Turan Y.; Cerrahoglu L.; Yurtkuran M.; Calis M.; Tas N.; Ozgocmen S.; Yoleri O.; Durmaz B.; Oncel S.; Tuncer T.; Sendur O.; Birtane M.; Tuzun F.; Bingol U.; Kirnap M.; Celik Erturk G.; Ardicoglu O.; Memis A.; Atamaz F.; Kizil R.; Kacar C.; Gurer G.; Uzunca K.; Sari H.
    The Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire is a disease-specific measure of needs-based quality of life developed in the UK and the Netherlands. This study describes translation, validation, and reliability of the scale into Turkish population. The ASQoL was translated into Turkish using the dual-panel process. Content validity was assessed via cognitive debriefing interviews with ankylosing spondylitis (AS) patients. Patients with AS according to modified New York criteria were recruited into the study from 12 hospitals of all part of Turkey. Psychometric and scaling properties were assessed via a two administration survey involving the ASQoL, the Nottingham Health Profile (NHP), Bath AS Functional Index (BASFI), and Bath AS Disease Activity Index (BASDAI). Classical psychometrics assessed reliability, convergent validity (correlation of ASQoL with NHP, BASFI, and BASDAI) and discriminative validity (correlation of ASQoL with perceived AS-severity and general health). Cognitive debriefing showed the new Turkish ASQoL to be clear, relevant, and comprehensive. Completed survey questionnaires were received from 277 AS patients (80 % Male, mean age 42.2/SD 11.6, mean AS duration 9.4 years/SD 9.4). Test-retest reliability was excellent (0.96), indicating low random measurement error for the scale. Correlations of ASQoL with NHP sections were low to moderate (NHP Sleep 0.34; NHP Emotional Reactions 0.83) suggesting the measures assess related but distinct constructs. The measure was able to discriminate between patients based on their perceived disease severity (p < 0.0001) and self-reported general health (p < 0.0001). The Turkish version of ASQoL has good reliability and validity properties. It is practical and useful scale to assess the quality of life in AS patients in Turkish population. © 2013 Springer-Verlag Berlin Heidelberg.
  • No Thumbnail Available
    Item
    Antifungal consumption, indications and selection of antifungal drugs in paediatric tertiary hospitals in Turkey: Results from the first national point prevalence survey
    (Elsevier Ltd, 2018) Çağlar İ.; Devrim İ.; Özdemir H.; Şahbudak Z.; Sönmez G.; Buyukcam A.; Gulhan B.; Kara A.; Aygun D.F.; Bayram N.; Celebi S.; Çetin B.; Nepesov M.İ.; Yilmaz A.T.; Kepenekli E.; Çiftdogan D.Y.; Acar M.K.; Yayla B.C.; Okumuş C.; Ecevit Z.; Hatipoglu N.; Kuyucu N.; Kosker M.; Sen S.; Karbuz A.; Sutcu M.; Duramaz B.B.; Özen M.; Çiftçi E.; Alabaz D.; Kurugol Z.; Kara A.; Kanik S.; Kilic O.; Oncel S.; Somer A.; Tapisiz A.; Belet N.; Akcan Ö.M.; Türel Ö.; Ozkaya A.; Tezer H.; Cengiz A.B.; İnce E.; Camcioglu Y.; Kocabas E.; Arisoy E.S.; Salman N.
    Objectives: The aim of this point prevalence survey was to evaluate the consumption, indications and strategies of antifungal therapy in the paediatric population in Turkey. Methods: A point prevalence study was performed at 25 hospitals. In addition to general data on paediatric units of the institutes, the generic name and indication of antifungal drugs, the presence of fungal isolation and susceptibility patterns, and the presence of galactomannan test and high-resolution computed tomography (HRCT) results were reviewed. Results: A total of 3338 hospitalised patients were evaluated. The number of antifungal drugs prescribed was 314 in 301 patients (9.0%). Antifungal drugs were mostly prescribed in paediatric haematology and oncology (PHO) units (35.2%), followed by neonatal ICUs (NICUs) (19.6%), paediatric services (18.3%), paediatric ICUs (PICUs) (14.6%) and haematopoietic stem cell transplantation (HSCT) units (7.3%). Antifungals were used for prophylaxis in 147 patients (48.8%) and for treatment in 154 patients (50.0%). The antifungal treatment strategy in 154 patients was empirical in 77 (50.0%), diagnostic-driven in 29 (18.8%) and targeted in 48 (31.2%). At the point of decision-making for diagnostic-driven antifungal therapy in 29 patients, HRCT had not been performed in 1 patient (3.4%) and galactomannan test results were not available in 12 patients (41.4%). Thirteen patients (8.4%) were receiving eight different antifungal combination therapies. Conclusion: The majority of antifungal drugs for treatment and prophylaxis were prescribed in PHO and HSCT units (42.5%), followed by ICUs. Thus, antifungal stewardship programmes should mainly focus on these patients within the availability of diagnostic tests of each hospital. © 2018 International Society for Chemotherapy of Infection and Cancer
  • No Thumbnail Available
    Item
    Evaluation of 601 children with multisystem inflammatory syndrome (Turk MISC study)
    (Springer Science and Business Media Deutschland GmbH, 2023) Yilmaz D.; Ekemen Keles Y.; Emiroglu M.; Duramaz B.B.; Ugur C.; Aldemir Kocabas B.; Celik T.; Ozdemir H.; Bayturan S.; Turel O.; Erdeniz E.H.; Cakici O.; Cakmak Taskin E.; Erbas İ.C.; Genceli M.; Sari E.E.; Caymaz C.; Kizil M.C.; Sutcu M.; Demirbuga A.; Alkan G.; Bagcı Z.; Timurtas Dayar G.; Ozkan E.A.; Tekin Yilmaz A.; Akca M.; Yesil E.; Kara S.S.; Akturk H.; Yasar B.; Umit Z.; Uygun H.; Erdem N.; Buyukcam A.; Karadag Oncel E.; Tuter Oz S.K.; Cetin H.S.; Anil A.B.; Yilmaz R.; Zengin N.; Uzuner S.; Albayrak H.; Borakay O.; Topal S.; Arslan G.; Yazar A.; Ozer A.; Kendirli T.; Kara E.M.; Demirkol D.; Battal F.; Kosker M.; Metin Akcan O.; Kihtir H.S.; Gul D.; Zararci K.; Alakaya M.; Kula N.; Celik E.; Petmezci E.; Evren G.; Kara Aksay A.; Konca C.; Sert A.; Arslan D.; Bornaun H.; Tekeli O.; Bal A.; Sahin I.O.; Demir S.; Sap F.; Akyol M.B.; Tanidir I.C.; Donmez Y.N.; Ucar T.; Coban S.; Arga G.; Hancerli Torun S.; Karpuz D.; Celik S.F.; Varan C.; Elmali F.; Oncel S.; Belet N.; Hatipoglu N.; Dalgic Karabulut N.; Turgut M.; Somer A.; Kuyucu N.; Dinleyici E.C.; Ciftci E.; Kara A.
    Purpose: Due to its link with the 2019 coronavirus, the multisystem inflammatory syndrome in children (MISC) has garnered considerable international interest. The aim of this study, in which MISC patients were evaluated multicenter, and the data of the third period of the Turk-MISC study group, to compare the clinical and laboratory characteristics and outcomes of MISC patients who did and did not require admission to an intensive care unit (ICU). Methods: This retrospective multicenter observational study was carried out between June 11, 2021, and January 01, 2022. The demographics, complaints, laboratory results, system involvements, and outcomes of the patients were documented. Results: A total of 601 patients were enrolled; 157 patients (26.1%) required hospitalization in the intensive care unit (ICU). Median age was 8 years (interquartile range (IQR) 4.5–11.3 years. The proportion of Kawasaki disease-like features in the ICU group was significantly higher than in the non-ICU group (56.1% vs. 43.2% p = 0.006). The ICU group had considerably lower counts of both lymphocytes and platelets (lymphocyte count 900 vs. 1280 cells × μL, platelet count 153 vs. 212 cells × 103/ μL, all for p< 0.001). C-reactive protein, procalcitonin, and ferritin levels were significantly higher in the ICU group (CRP 164 vs. 129 mg/L, procalcitonin 9.2 vs. 2.2 μg/L, ferritin 644 vs. 334 μg/L, all for p< 0.001). Being between ages 5–12 and older than 12 increased the likelihood of hospitalization in the ICU by four [95% confidence intervals (CI)1.971–8.627] and six times (95% CI 2.575–14.654), respectively, compared to being between the ages 0–5. A one-unit increase in log d-dimer (µg/L) and log troponin (ng/L) was also demonstrated to increase the need for intensive care by 1.8 (95% CI 1.079–3.233) and 1.4 times (95% CI 1.133–1.789), respectively. Conclusion: By comparing this study to our other studies, we found that the median age of MISC patients has been rising. Patients requiring an ICU stay had considerably higher levels of procalcitonin, CRP, and ferritin but significantly lower levels of lymphocyte and thrombocyte. In particular, high levels of procalcitonin in the serum might serve as a valuable laboratory marker for anticipating the need for intensive care. What is Known: • Lymphopenia and thrombocytopenia were an independent predictor factors in patients with MISC who needed to stay in intensive care unit. • The possibility of the need to stay in the intensive care unit in patients with MISC who had Kawasaki disease-like findings was controversial compared with those who did not. What is New: • A one-unit increase log D dimer and log troponin was demonstrated to require for intensive care unit by 1.8 and 1.4 times, respectively. • Serum procalcitonin levels had the best performance to predict stay in the intensive care unit stay. © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.